Toxicities frequently compromise the ability to dose HU at therapeutic levels1
More than 1 out of every 8 PV patients receiving HU is intolerant to the drug based on ELN criteria2
Rate of HU intolerance2

Patients with HU intolerance or HU resistance have had limited therapeutic options
- For 59% of patients with HU resistance/intolerance in a Phase III clinical trial, HU was nonetheless considered their best available treatment3*